The Good, the Bad, and the Hoax: When Publication Instantaneously Impacts Treatment Strategies for COVID-19
- 22 July 2020
- journal article
- letter
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 64 (8)
- https://doi.org/10.1128/aac.01127-20
Abstract
The COVID-19 pandemic is an unprecedented situation with physicians awaiting information on therapeutic advances to an extent hardly ever seen in medical history.….This publication has 7 references indexed in Scilit:
- Updated Approaches against SARS-CoV-2Antimicrobial Agents and Chemotherapy, 2020
- A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19The New England Journal of Medicine, 2020
- Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection A Randomized Clinical TrialJAMA Network Open, 2020
- No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infectionMedecine Et Maladies Infectieuses, 2020
- Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trialInternational Journal of Antimicrobial Agents, 2020
- Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findingsThorax, 2004